Vistin Pharma ASA Reports Financial Results for Q2 2024
Vistin Pharma ASA (VISTN) has announced its financial results for the second quarter of 2024, highlighting successful operations despite facing market challenges.
Revenue Growth and Sales Volume Analysis
During the second quarter, Vistin Pharma achieved a revenue of MNOK 106, which is a slight dip from MNOK 107 in the same quarter last year. However, the sales volume saw a 4% increase compared to Q2 2023, and currency-neutral sales grew by 1%. For the first half of 2024, total revenue reached MNOK 210, slightly surpassing the MNOK 208 reported in the first half of the previous year.
EBITDA Improvement and Profitability Gains
The earnings before interest, taxes, depreciation, and amortization (EBITDA) for the second quarter showed a significant improvement, rising to MNOK 27, which marks a 40% increase from the MNOK 20 recorded in Q2 2023. This growth is attributed to a favorable product mix, lower material costs, and effective cost management throughout the quarter. For the first half of 2024, EBITDA totaled MNOK 48, reflecting a substantial 42% increase compared to MNOK 34 from the previous year.
Net Profit Insights
The net profit for the second quarter of 2024 was MNOK 19.2. This figure includes a positive impact of around MNOK 2.5, which is linked to the fair value of future foreign exchange cash flow hedging contracts. It’s important to note that this gain is unrealized and does not influence cash flow for the current period.
Plans for Dividend Distribution
In June 2024, Vistin Pharma announced a cash dividend of NOK 0.50 per share, with an additional dividend of NOK 0.50 per share planned for distribution in the fourth quarter of the year. These financial strategies underscore the company’s commitment to enhancing shareholder value.
Details on Upcoming Conference Call
Vistin Pharma will hold a conference call today at 8:30 AM CET to discuss the quarterly results. Participants can join the call through a webcast or by telephone, ensuring accessibility for both analysts and investors.
Information on Accessing the Conference Call
The conference call will be conducted in English, offering insights into the company's performance and strategic direction. Additional information about the call will be available on the company’s official website.
Company Overview and Future Prospects
Vistin Pharma ASA is dedicated to innovative pharmaceutical development, targeting niche markets that require specialized products. The company is actively exploring new growth opportunities while maintaining a strong presence in the industry, emphasizing its commitment to quality and efficiency.
Contact Information
For further details regarding Vistin Pharma and their financial results, interested parties can reach out to:
Alexander Karlsen
CFO
+47 97 05 36 21
alexander.karlsen@vistin.com
Frequently Asked Questions
What are Vistin Pharma's key financial metrics for Q2 2024?
Vistin Pharma reported a revenue of MNOK 106 and an EBITDA of MNOK 27, reflecting strong growth and profitability.
How did sales volume change compared to last year?
The sales volume increased by 4% compared to Q2 2023, indicating healthy demand for their products.
What contributed to the increase in EBITDA?
The notable increase in EBITDA was driven by a favorable product mix, decreased material costs, and effective cost control measures.
Is there a dividend plan for shareholders?
Yes, Vistin Pharma intends to distribute a cash dividend of NOK 0.50 per share, with an additional dividend of the same amount scheduled for later this year.
How can interested parties access the conference call?
Participants can join the conference call through a webcast or phone registration, with details available on the company’s official platforms.
